Mice administered FOLFIRINOX through the implantable device had greater tumor regression and lower tissue toxicity.
Pancreatic cancer is a disease with dismal survival rates (less than 5%) and the second only to non-small cell lung cancer for cancer-related deaths in the United States. A major challenge with treating this disease has been the stromal milieu that surrounds the solid tumor and forms a rigid, impenetrable barrier for chemotherapy. Now, scientists at the University of North Carolina at Chapel Hill have developed a technology that, at least in animal models, has found an Achilles Heel in these tumors.
The researchers have invented an implantable device that can deliver the highly toxic and promising drug cocktail of folinic acid (leucovorin), fluorouracil, irinotecan, and oxaliplatin (together called FOLFIRINOX), directly to the tumor.
“We use the device to hit the primary tumor hard. It’s an exciting approach because there is so little systemic toxicity that it leaves room to administer additional drugs against cancer cells that may have spread in the rest of the body,” according to senior author Jen Jen Yeh, MD, senior author on the study.
According to the paper, published in the Proceedings of the National Academy of Sciences, the iontophoretic device was surgically implanted onto orthotopic patient-derived pancreatic tumors in mice, and the animals were administered saline or FOLFIRINOX through the device, or saline or FOLFIRINOX intravenously (IV). Tumor volumes were measured following treatment completion.
The authors found that 50% of mice who received FOLFIRINOX through the device had significant tumor regression and 1 mouse had stable disease. The mean log2-fold change in tumor volume were 0.4 in mice that received device FOLFIRINOX, 1.9 for IV FOLFIRINOX, 3 for IV saline, and 2.6 for device saline. Additionally, when the tumor tissues were stained for a cell proliferation marker, Ki-67, mice who received FOLFIRINOX through the device had significantly lower expression of the marker, indicating regression of tumor growth. Another important finding of the study was the reduced levels of tissue toxicity with the implanted device, which indicates that these toxic drugs may be better tolerated by patients, and might even improve their quality of life.
“The beauty of this device is that all of the drug delivery is focused locally, with low delivery to the rest of the body,” said James D. Byrne, PhD, the paper’s first author. “If this works in humans, we hope the device can be used as a plug-and-play approach to delivering the latest, most promising drug regimens for patients who have a dire need for new and better treatments.”
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More